[
  {
    "uuid": "35af02a74d58520eb3ca4ca128df6659db49792e",
    "url": "https://www.etfdailynews.com/2023/12/28/ishares-msci-eafe-value-etf-batsefv-shares-bought-by-simplicity-wealth-llc/",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "MarketBeat News",
    "published": "2023-12-29T01:03:00Z",
    "title": "iShares MSCI EAFE Value ETF (BATS:EFV) Shares Bought by Simplicity Wealth LLC",
    "text": "Simplicity Wealth LLC increased its holdings in shares of iShares MSCI EAFE Value ETF (\nBATS:EFV – Free Report) by 20.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,505 shares of the company’s stock after buying an additional 30,916 shares during the period. iShares MSCI EAFE Value ETF comprises approximately 5.1% of Simplicity Wealth LLC’s portfolio, making the stock its 5th largest position. Simplicity Wealth LLC owned 0.05% of iShares MSCI EAFE Value ETF worth $8,734,000 at the end of the most recent quarter.\nA number of other institutional investors have also recently added to or reduced their stakes in EFV. RTD Financial Advisors Inc. raised its position in iShares MSCI EAFE Value ETF by 1.3% during the 3rd quarter. RTD Financial Advisors Inc. now owns 166,555 shares of the company’s stock worth $8,150,000 after purchasing an additional 2,058 shares during the last quarter. SOL Capital Management CO raised its position in shares of iShares MSCI EAFE Value ETF by 7.0% during the third quarter. SOL Capital Management CO now owns 67,592 shares of the company’s stock worth $3,307,000 after acquiring an additional 4,425 shares during the last quarter. Syntegra Private Wealth Group LLC lifted its stake in shares of iShares MSCI EAFE Value ETF by 30.3% in the third quarter. Syntegra Private Wealth Group LLC now owns 9,042 shares of the company’s stock worth $442,000 after acquiring an additional 2,102 shares during the period. Flagstar Advisors Inc. bought a new stake in iShares MSCI EAFE Value ETF in the third quarter valued at approximately $240,000. Finally, RDA Financial Network bought a new stake in iShares MSCI EAFE Value ETF in the third quarter valued at approximately $260,000.\niShares MSCI EAFE Value ETF Stock Up 0.5 %\niShares MSCI EAFE Value ETF stock traded up $0.28 during mid-day trading on Thursday, hitting $52.18. 1,526,731 shares of the stock were exchanged. The firm’s fifty day simple moving average is $49.73 and its two-hundred day simple moving average is $49.41. iShares MSCI EAFE Value ETF has a 12 month low of $49.15 and a 12 month high of $59.57. The stock has a market capitalization of $17.53 billion, a price-to-earnings ratio of 9.51 and a beta of 0.84.\niShares MSCI EAFE Value ETF Profile\nFree Report)\niShares MSCI EAFE Value ETF (the Fund), formerly iShares MSCI EAFE Value Index Fund, is an exchange-traded fund (ETF). The Fund seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI EAFE Value Index. The Index is a subset of the MSCI EAFE Index and constituents of the Index include securities from Europe, Australasia (Australia and Asia), and the Far East.\nFurther Reading\nFive stocks we like better than iShares MSCI EAFE Value ETF What is a Non-Fungible Token (NFT)? Definition and How it Works How to invest in vertical farming stocks Low PE Growth Stocks: Unlocking Investment Opportunities What is the penalty for excess contributions to an IRA? How to Buy Cheap Stocks Step by Step How to invest in the top grocery stocks\nReceive News & Ratings for iShares MSCI EAFE Value ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares MSCI EAFE Value ETF and related companies with\nMarketBeat.com's FREE daily email newsletter.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology",
      "Economy, Business and Finance",
      "Health"
    ],
    "external_links": [
      "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=BATS&Symbol=EFV",
      "https://www.marketbeat.com/originals/how-to-invest-in-vertical-farming-stocks/",
      "https://www.marketbeat.com/originals/grocery-stocks/",
      "https://www.marketbeat.com/market-data/low-pe-growth-stocks/",
      "https://www.marketbeat.com/originals/what-is-the-penalty-for-excess-contributions-to-an-ira/",
      "https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&RegistrationCode=NewsSites-SeeAlso",
      "https://www.marketbeat.com/stocks/BATS/EFV/",
      "https://www.marketbeat.com/market-data/low-priced-stocks/",
      "https://www.marketbeat.com/compare-stocks/non-fungible-token-stocks/",
      "https://marketbeat.com/originals/grocery-stocks/",
      "https://marketbeat.com/originals/how-to-invest-in-vertical-farming-stocks/",
      "https://marketbeat.com/compare-stocks/non-fungible-token-stocks/",
      "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx",
      "https://marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&RegistrationCode=NewsSites-SeeAlso",
      "https://www.marketbeat.com/market-data/low-pe-growth-stocks",
      "https://www.marketbeat.com/market-data/low-priced-stocks",
      "https://www.marketbeat.com/originals/grocery-stocks",
      "https://www.marketbeat.com/originals/what-is-the-penalty-for-excess-contributions-to-an-ira",
      "https://www.marketbeat.com/compare-stocks/non-fungible-token-stocks",
      "https://marketbeat.com/stocks/BATS/EFV/",
      "https://marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=BATS&Symbol=EFV",
      "https://www.marketbeat.com/newsletter/PDFoffer.aspx",
      "https://marketbeat.com/market-data/low-priced-stocks/",
      "https://marketbeat.com/market-data/low-pe-growth-stocks/",
      "https://marketbeat.com/originals/what-is-the-penalty-for-excess-contributions-to-an-ira/",
      "https://www.marketbeat.com/originals/how-to-invest-in-vertical-farming-stocks",
      "https://www.marketbeat.com/stocks/BATS/EFV"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [
        {
          "name": "simplicity wealth llc simplicity wealth llc",
          "sentiment": "negative"
        },
        {
          "name": "securities and exchange commission",
          "sentiment": "none"
        },
        {
          "name": "sec",
          "sentiment": "none"
        },
        {
          "name": "rtd financial advisors inc.",
          "sentiment": "none"
        },
        {
          "name": "simplicity wealth llc",
          "sentiment": "none"
        },
        {
          "name": "sol capital management co",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "rating": null,
    "crawled": "2023-12-29T04:08:41.022+02:00",
    "updated": "2023-12-29T04:08:41.022+02:00"
  },
  {
    "uuid": "7e6cb47d4bb9bdde4656b170870d0e96fa1544fb",
    "url": "https://dailyclout.io/democrats-panic-over-president-trump-serving-fries",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Drew Allen",
    "published": "2024-10-24T16:27:00Z",
    "title": "“Democrats Panic Over President Trump Serving Fries”",
    "text": "Drew Allen explains why he believes Vice President Kamala Harris is the least qualified Presidential candidate in history. She was asked again by a reporter what she would do differently than President Biden, and her answer will shock you. New polling shows that Vice President Kamala Harris is outperforming both President Biden and former Democrat nominee Hillary Clinton, with women over the age of fifty. Their most important issue? The economy.\nPlus, Former President Trump enrages Democrats with his political stunt at McDonald’s. Finally, U.S. intel is leaked exposing Israel’s plans to strike Iran. Is this the biggest scandal no Democrat is talking about?\n“Follow ‘The Drew Allen Show on DailyClout’ on Rumble! https://rumble.com/c/TheDrewAllenShowOnDailyClout/videos\nPlease Support Our Sponsors:\nBirch Gold Group: “A Gold IRA from Birch Gold Group is the ultimate inflation hedge for your savings in uncertain times. Visit https://birchgold.com/dailyclout to see how to protect your IRA or 401(k).”\nThe Wellness Company: https://dailyclouthealth.com\nUse code DREWALLEN for 10% off!\nNativePath: “Collagen supplements help you replace what you stop producing — and the studies speak for themselves. Visit https://getnativepath.com/dailyclout for a MASSIVE 45% discount plus free shipping!”\nBiOptimizers: “Over 75% of the population is magnesium deficient. Nurture your mind and body with this all-natural, full-spectrum magnesium supplement. Go to https://bioptimizers.com/dailyclout and use promo code DAILYCLOUT for 10% off!”\nPatriot Mobile: “Visit https://patriotmobile.com/dailyclout for a FREE month of service when you switch!”\nOrder ‘The Pfizer Papers’ and Support Our Historic Work: https://www.amazon.com/dp/1648210376?&tag=skyhorsepub-20\nDiscover LegiSector! Stay up-to-date on issues you care about with LegiSector’s state-of-the-art summarizing capabilities and customizable portals. No researchers needed, no lobbyists, no spin. Legislation at your fingertips! Learn more at https://www.legisector.com/",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Politics"
    ],
    "ai_allow": true,
    "canonical": false,
    "webz_reporter": false,
    "external_links": [
      "https://dailyclouthealth.com/",
      "https://getnativepath.com/dailyclout",
      "https://patriotmobile.com/dailyclout",
      "https://www.legisector.com/",
      "http://www.amazon.com/exec/obidos/ASIN/1648210376",
      "https://dailyclouthealth.com",
      "https://birchgold.com/dailyclout",
      "https://rumble.com/embed/v5hoynl/?pub=mbdkr&rel=0&autoplay=0",
      "https://rumble.com/embed/v5hoynl/?pub=mbdkr&#038;rel=0&#038;autoplay=0",
      "https://rumble.com/c/TheDrewAllenShowOnDailyClout/videos",
      "https://bioptimizers.com/dailyclout",
      "https://www.bioptimizers.com/dailyclout",
      "https://www.dailyclouthealth.com",
      "https://www.getnativepath.com/dailyclout",
      "https://www.rumble.com/embed/v5hoynl/?pub=mbdkr&#038;rel=0&#038;autoplay=0",
      "https://www.birchgold.com/dailyclout",
      "https://rumble.com/embed/v5hoynl/",
      "https://dailyclouthealth.com",
      "https://www.dailyclouthealth.com/",
      "http://amazon.com/exec/obidos/ASIN/1648210376",
      "https://www.legisector.com",
      "https://www.patriotmobile.com/dailyclout",
      "https://www.rumble.com/embed/v5hoynl/?pub=mbdkr&rel=0&autoplay=0",
      "https://legisector.com/",
      "https://www.rumble.com/c/TheDrewAllenShowOnDailyClout/videos"
    ],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Kamala Harris",
          "sentiment": "negative"
        },
        {
          "name": "Hillary Clinton",
          "sentiment": "none"
        },
        {
          "name": "Biden",
          "sentiment": "none"
        },
        {
          "name": "Trump",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "Birch Gold Group",
          "sentiment": "none"
        },
        {
          "name": "McDonald",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-10-25T00:43:53.832+03:00",
    "updated": "2024-10-25T00:43:53.832+03:00"
  },
  {
    "uuid": "6e7b9b66503d5091663074c8a6a5135bf2482661",
    "url": "https://firenze.repubblica.it/cronaca/2024/08/02/news/allerta_temporali_toscana_firenze_caldo_bollino_rosso-423428399",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "di Margherita Cecchin",
    "published": "2024-08-02T12:17:00Z",
    "title": "Allerta temporali in Toscana, ma resta il caldo: a Firenze ancora un weekend da bollino rosso - la Repubblica",
    "text": "Primo weekend di agosto ancora caratterizzato dal caldo in Toscana, ma anche dalla pioggia. In particolare per la giornata di sabato 3 agosto la Sala operativa unificata della Protezione civile regionale ha emesso un’allerta meteo di codice giallo per rischio di temporali forti , dalle 11 alle 18: le possibili precipitazioni interesseranno tutte le province, tranne le zone costiere. Previsti ombrelli aperti anche a Firenze, dove continuerà l’allerta caldo da bollino rosso , estesa fino a domenica 4 agosto.\nLa previsione dell’allerta da ondata di calore per tutto il fine settimana è riportata dal bollettino diffuso dal Comune di Firenze, che ricorda inoltre il codice giallo per temporali nella stessa fascia oraria regionale. Come spiegato ancora dalla Regione l’instabilità atmosferica, con conseguente attenuazione dell’attuale alta pressione, sarà dovuta a infiltrazioni di aria fresca in quota.\nPer la giornata di oggi, venerdì 2 agosto , possibili temporali isolati su crinali appenninici e sull’Amiata. Per sabato 3 invece, a partire dalla tarda mattinata e primo pomeriggio, sono attesi temporali sparsi che partiranno dalle zone orientali della regione per poi spostarsi verso quelle occidentali. Come anticipato, nell’allerta sono comprese tutte le province tranne la costa, esclusa la Lunigiana. Possibili localmente eventi significativi nelle zone interne e montuose, colpi di vento e grandinate.\nPer quanto riguarda le temperature , dalle previsioni del Consorzio Lamma per sabato 3 minime stazionarie e massime in diminuzione: nelle province toscane si va da una minima di 22 gradi ad una massima di 34 gradi, segnalata per Firenze, Prato e Grosseto. Per domenica 4 cielo previsto sereno o poco nuvoloso, possibili addensamenti sui rilievi, temperature massime in aumento con punte di 35-37 gradi in pianura e minime in calo nelle zone interne. Le massime indicate per Firenze, ma anche per Prato e Pistoia, sono di 36 gradi.\nLeggi i commenti I commenti dei lettori",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "italian",
    "sentiment": "negative",
    "categories": [
      "Weather",
      "Lifestyle and Leisure"
    ],
    "webz_reporter": false,
    "external_links": [
      "http://www.repstatic.it/cless/main/nazionale/2020-v1/include/detail/paywall.html",
      "http://www.repstatic.it/cless/main/nazionale/2020-v1/include/detail/under-content.html--",
      "https://www.repstatic.it/cless/common/widget/newsletter/2018-v1/include/gedi-newsletter-cx.html",
      "http://www.repstatic.it/cless/common/box/outbrain/2022-v1/include/short.html",
      "https://repstatic.it/cless/common/widget/newsletter/2018-v1/include/gedi-newsletter-cx.html",
      "http://repstatic.it/cless/common/box/outbrain/2022-v1/include/short.html",
      "http://repstatic.it/cless/main/nazionale/2020-v1/include/detail/paywall.html",
      "http://repstatic.it/cless/main/nazionale/2020-v1/include/detail/under-content.html--"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-08-02T17:38:40.781+03:00",
    "updated": "2024-08-02T17:38:40.781+03:00"
  },
  {
    "uuid": "ddcae5ec52dd4ca95d74155b8603ffe15abac439",
    "url": "https://www.superdeporte.es/valencia-cf/2024/01/07/brentford-dejaban-chutar-ahora-canos-secreto-goles-96637749.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Iván Carsí",
    "published": "2024-01-07T22:20:00Z",
    "title": "Canós: \"En el Brentford no me dejaban chutar y ahora me insisten en que pruebe\"",
    "text": "Sergi Canós fue uno de los protagonistas del duelo con su segundo gol como valencianista y el que inició la remontada en Cartagonova. El de Nules se ha mostrado muy contento por la victoria tras el encuentro: \"El gol es muy importante, siempre es bonito marcar y hemos podido empatar y luego darle la vuelta. Muy feliz y hay que seguir trabajando\".\nAsimismo el atacante valencianista reconoció que ha estado tranquilo hasta alcanzar este nivel en el equipo: \"Siempre he tenido confianza en mí mismo y la verdad es que ha sido un gran gol. Estoy muy contento de ayudar al equipo. He estado siete años sin que me dejaran chutar en el Brentford ahora me insisten en que pruebe”\nEl de Nules siguió el discurso del técnico y destacó la dificultad que han tenido los equipos de mayor categoría para superar esta ronda: Todos los partidos han sido muy difíciles para todos los equipos. Muchos Primeras han sufrido para poder pasar. Sí que es verdad que nos ha faltado un poquito más. Veremos en qué hemos fallado e intentaremos mejorar\".\nCanós avisa: \"El objetivo es jugar el próximo partido y ojalá nos toque en\nMestalla\".",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "positive",
    "categories": [
      "Sport",
      "Human Interest",
      "Crime, Law and Justice"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-01-08T00:40:25.239+02:00",
    "updated": "2024-01-08T00:40:25.239+02:00"
  },
  {
    "uuid": "afaa630f769a388366d6c4dcc4a7e9ec299902df",
    "url": "https://www.newsbreak.com/news/3822304232625-pappas-highlights-impact-of-republican-budget-proposal-on-health-and-seniors",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Byline: Press Release",
    "published": "2025-02-20T22:06:00Z",
    "title": "Pappas Highlights Impact of Republican Budget Proposal on Health and Seniors - NewsBreak",
    "text": "Pappas Highlights Impact of Republican Budget Proposal on Health and Seniors - NewsBreak",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Politics",
      "Health"
    ],
    "topics": [
      "Politics->healthcare policy",
      "Politics->government policy",
      "Health->health organisation",
      "Health->government health care"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": null,
    "rating": null,
    "crawled": "2025-02-21T00:16:34.761+02:00",
    "updated": "2025-02-21T00:37:23.541+02:00"
  },
  {
    "uuid": "3f8d13108112e77577fc77fc1bd3f4607b7bb960",
    "url": "https://www.rttnews.com/3469449/how-much-coffee-consumption-elevates-heart-attack-risk.aspx",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "RTTNews Staff Writer",
    "published": "2024-08-15T21:22:00Z",
    "title": "How Much Coffee Consumption Elevates Heart Attack Risk ?",
    "text": "A recent research, conducted by Zydus Medical College and Hospital in India, found that drinking too much coffee or any other caffeine-containing beverage could severely affect heart health .\nResearchers said that individuals who consume more than 400 mg of caffeine daily, equivalent to four cups of coffee, 10 cans of soda or two energy drinks, are at a higher risk of developing cardiovascular disease. The risk is more elevated in those who consume over 600 mg of caffeine daily.\n\"Due to its effect on the autonomic nervous system, regular caffeine consumption could put otherwise healthy individuals at risk of hypertension and other cardiovascular events,\" said lead researcher Dr. Nency Kagathara with Zydus Medical College and Hospital.\nThe study, presented at the American College of Cardiology's Asia scientific conference, involved 92 healthy people aged between 18 and 45 years. The participants reported their coffee consumption, and then underwent a three-minute step test to check their heart health.\nResearchers found that about 20 percent of the participants consumed over 400 mg of caffeine daily, with higher consumption noted among women, people working in business and management roles, and individuals living in urban areas.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Health",
      "Social Issue",
      "Science and Technology"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "nency kagathara",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "zydus medical college and hospital",
          "sentiment": "neutral"
        },
        {
          "name": "zydus medical college",
          "sentiment": "none"
        },
        {
          "name": "american college of cardiology",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "asia",
          "sentiment": "none"
        },
        {
          "name": "india",
          "sentiment": "none"
        }
      ]
    },
    "syndication": null,
    "rating": null,
    "crawled": "2024-08-16T00:49:45.066+03:00",
    "updated": "2024-08-16T00:49:45.066+03:00"
  },
  {
    "uuid": "f93d164279f66ac9573effe73943f5f5adab1fb1",
    "url": "https://www.bjpenn.com/mma-news/nobuyuki-sakakibara/rizins-nobuyuki-sakakibara-open-to-pfl-co-promotion-after-bellator-sale-doors-always-open/",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Josh Evanoff",
    "published": "2023-12-28T23:15:00Z",
    "title": "RIZIN’s Nobuyuki Sakakibara open to PFL co-promotion after Bellator sale: “Doors always open”",
    "text": "RIZIN’s Nobuyuki Sakakibara open to PFL co-promotion after Bellator sale: “Doors always open” RIZIN President Nobuyuki Sakakibara is open to working with PFL and Donn Davis, but it will take some time. The annual New Year’s event for RIZIN is slated for this weekend. Headlined by Kyoji Horiguchi’s rematch against Makoto Takahashi, the card also features high-profile names such as Juan Archuleta, Kai Asakura, John Dodson, and more. While a fun event, this year’s event will look radically different than last year’s. For those who remember, last December’s RIZIN’s New Year’s card featured Bellator. The entire main card featured top fighters from the two companies going back and forth. Ultimately, the [Scott Coker](https://www.bjpenn.com/mma-news/bellator/pfl-reportedly-offers-bellator-president-scott-coker-an-opportunity-to-stay-on/)-led brand went 5-0 that night, much to the chagrin of Nobuyuki Sakakibara. However, it was clear that night was just the beginning of the companies’ partnership. This July, the second RIZIN X Bellator card went down, and once again featured names such as [Patricio Pitbull](https://www.bjpenn.com/mma-news/bellator/patricio-pitbull-interested-in-ufc-signing-as-bellator-pfl-deal-looms-my-career-deserves-it/). However, that event will likely be the final between the two companies. In November, the Viacom-owned promotion was sold to the PFL. Since then, Donn Davis has revealed plans for the brand to be run as a separate entity. For RIZIN President Nobuyuki Sakakibara, the premise of [working with the PFL](https://www.bjpenn.com/mma-news/cris-cyborg-justino/claressa-shields-reveals-interest-in-pfl-dream-fight-with-cris-cyborg-its-the-scariest-fight-for-me/) is an interesting one. However, to make the event, they will need to build a relationship together. Speaking in a recent interview with MMA Fighting, Sakakibara stated that part of the reason why the Bellator partnership worked was his close relationship with Scott Coker. RELATED: [RIZIN’S NOBUYUKI SAKAKIBARA CONFIRMS TALKS WITH ANDERSON SILVA FOR RETIREMENT BOUT: “WE’RE ALWAYS OPEN”](https://www.bjpenn.com/mma-news/anderson-silva/rizins-nobuyuki-sakakibara-confirms-talks-with-anderson-silva-for-retirement-bout-were-always-open/) RIZIN’s Nobuyuki Sakakibara discusses potential PFL co-promotion “[Co-promoting] was all possible because of the relationship that we’ve had with Scott Coker,” Nobuyuki Sakakibara stated regarding a potential PFL partnership. “And this relationship has not been developed within just one or two years – this goes way back of working together and the trust and relationship that we’ve had. That’s the only reason why we could make this happen…And if promoters with the same open mind can work together like that, we can make these things happen. When two promoters get together and start thinking about what the best move is for the future of our sport, we can do that kind of stuff.” (h/t [MMA FIghting](https://www.mmafighting.com/2023/12/26/24009652/rizin-nobuyuki-sakakibara-bellator-pfl-one-japan-mma)) He continued, “We understand that Bellator is under a new ownership and all promoters have different motives, all promoters have different ways to promote and philosophies that are different. Obviously, if Donn Davis has that passion, if he sees the importance of what we’re doing, the concept of what we’re doing for the sport and for the future. … We call ourselves a fight federation, RIZIN Fighting Federation, we want to continue to work with as many promoters as possible that share the same vision. “I understand that Donn Davis has his ambitions and plans.” Nobuyuki Sakakibara concluded. “So if we can make things work, our doors are always open.” What do you make of these comments? Do you want to see a RIZIN vs. PFL card in 2024? Topics: [Nobuyuki Sakakibara](https://www.bjpenn.com/mma-news/nobuyuki-sakakibara/) [Professional Fighters League (PFL)](https://www.bjpenn.com/mma-news/professional-fighters-league/) [RIZIN FF](https://www.bjpenn.com/mma-news/rizin-ff/)",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Sport",
      "Economy, Business and Finance",
      "Arts, Culture and Entertainment"
    ],
    "external_links": [
      "https://www.mmafighting.com/2023/12/26/24009652/rizin-nobuyuki-sakakibara-bellator-pfl-one-japan-mma",
      "https://mmafighting.com/2023/12/26/24009652/rizin-nobuyuki-sakakibara-bellator-pfl-one-japan-mma"
    ],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "nobuyuki sakakibara",
          "sentiment": "negative"
        },
        {
          "name": "bellator",
          "sentiment": "negative"
        },
        {
          "name": "makoto takahashi",
          "sentiment": "none"
        },
        {
          "name": "john dodson",
          "sentiment": "none"
        },
        {
          "name": "kyoji horiguchi",
          "sentiment": "none"
        },
        {
          "name": "juan archuleta",
          "sentiment": "none"
        },
        {
          "name": "scott coker",
          "sentiment": "none"
        },
        {
          "name": "donn davis",
          "sentiment": "none"
        },
        {
          "name": "kai asakura",
          "sentiment": "none"
        },
        {
          "name": "patricio pitbull",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "pfl",
          "sentiment": "negative"
        },
        {
          "name": "viacom",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "rating": null,
    "crawled": "2023-12-29T02:56:18.765+02:00",
    "updated": "2023-12-29T04:14:12.186+02:00"
  },
  {
    "uuid": "bca815999b007f74615237a9a5c6df1401aea6c8",
    "url": "https://www.devdiscourse.com/article/technology/3126040-easing-export-controls-boost-for-us-space-industry",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Devdiscourse News Desk",
    "published": "2024-10-17T19:51:00Z",
    "title": "Easing Export Controls: Boost for U.S. Space Industry | Technology",
    "text": "The Biden administration has relaxed export restrictions on U.S. commercial space companies, enabling easier shipment of satellite and spacecraft-related items to allies. This move aims to enhance the U.S. space industry's competitiveness, grow international partnerships, and support national security and foreign policy interests. Devdiscourse News Desk | Updated: 18-10-2024 03:51 IST | Created: 18-10-2024 03:51 IST\nThis image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only. SHARE In a significant move to bolster the U.S. space industry, the Biden administration has eased export restrictions for American commercial space companies. The decision will allow these companies to more easily ship satellite and spacecraft-related items to international allies and partners, according to officials.\nThe adjustments, published in the Federal Register, are designed to benefit major U.S. players like SpaceX and defense giants such as Lockheed Martin. The Department of Commerce emphasized that these changes aim to reduce the regulatory burden and stimulate innovation, all while safeguarding national security.\nThe rule modifications could play a crucial role in strengthening international alliances and supporting economic growth. Certain items will no longer require export licenses to Australia, Canada, and the U.K. This aligns with the goals of the AUKUS security pact and enhances cooperation in the Indo-Pacific region, countering China's rising influence.\n(With inputs from agencies.)\nREAD MORE ON: Biden administration export restrictions U.S. space industry SpaceX Lockheed Martin Commerce Department AUKUS foreign policy national security satellite exports Advertisement ALSO READ AUKUS Allies Push Boundaries with Uncrewed Naval Control U.S. Commerce Department Adds Chinese Firms to Unverified List POST / READ COMMENTS",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Economy, Business and Finance",
      "Science and Technology"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "Biden",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "U.S. Space Industry",
          "sentiment": "negative"
        },
        {
          "name": "Department of Commerce",
          "sentiment": "none"
        },
        {
          "name": "Lockheed Martin",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-10-18T01:47:25.012+03:00",
    "updated": "2024-10-18T03:18:24.410+03:00"
  },
  {
    "uuid": "159a99326be00e08eb389d03cfd1c00938842767",
    "url": "https://investorshangout.com/adcentrx-therapeutics-shares-exciting-data-for-nectin4-adc-270689-",
    "ord_in_thread": 0,
    "author": "Evelyn Baker",
    "published": "2025-04-23T23:10:00Z",
    "title": "Adcentrx Therapeutics Shares Exciting Data for Nectin-4 ADC",
    "text": "Adcentrx Therapeutics Shares Exciting Data for Nectin-4 ADC\nEvelyn BakerUpdated: 04-23-2025 07:10 PM\nExciting Developments in Cancer Therapy\nAdcentrx Therapeutics, a forward-thinking biotechnology company dedicated to revolutionizing the treatment of cancer with Antibody-Drug Conjugate (ADC) therapies, is set to unveil significant clinical data for its innovative product, ADRX-0706. This announcement is highly anticipated as it details crucial findings from the company's ongoing clinical research.\nShowcasing Clinical Advancements\nAt the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, Adcentrx will present interim data from the Phase 1a dose escalation trial of ADRX-0706, a highly targeted Nectin-4 ADC. This initial analysis highlights the promising attributes of ADRX-0706, specifically its differentiated safety and pharmacokinetic profile. The data indicates a notably reduced incidence of adverse events, such as peripheral neuropathy, a significant concern in cancer therapies.\nTrial Design and Objectives\nThe Phase 1a/b study remains open-label and is being conducted across multiple U.S. sites. The primary goal of Phase 1a was to explore the safety and tolerability of ADRX-0706 while determining the recommended dose for the subsequent Phase 1b. Results thus far have encouraged further investigation into ADRX-0706's impact on various advanced solid tumors, including urothelial, triple-negative breast, and cervical cancers.\nAbstract Highlights from ASCO\nThe poster titled \"Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors\" will present a comprehensive overview of the trial. Attendees can look forward to insights shared on June 2, focusing on the key aspects of developmental therapeutics and molecularly targeted agents.\nInnovative i-Conjugation® Technology\nAt the core of Adcentrx’s success is its proprietary i-Conjugation® technology. This platform is instrumental in formulating ADCs, utilizing advanced linkers and stable conjugation methods to facilitate effective drug delivery. By ensuring a high degree of stability, Adcentrx's ADCs are poised to offer patient-friendly therapeutic solutions.\nADRX-0706: A Game Changer in Cancer Treatment\nADRX-0706 represents a cutting-edge ADC created through the company’s mastery in design and development. Targeting Nectin-4, an adhesion protein prevalent in several solid tumors, this therapy integrates a proprietary tubulin inhibitor payload, AP052, leveraging the benefits of i-Conjugation® technology.\nThis innovative agent showcases an ideal drug-antibody ratio, allowing for enhanced therapeutic efficacy while maintaining a favorable safety profile, as indicated in preclinical trials. As it progresses to Phase 1b clinical trials, expectations are high regarding its implications for cancer treatment.\nFuture Directions and Trials\nThe evolution of ADRX-0706 promises better outcomes for patients who currently face limited treatment alternatives. With ongoing clinical evaluations, the research underscores Adcentrx's commitment to transforming oncology care through targeted and efficient drug delivery methodologies.\nAbout Adcentrx Therapeutics\nAdcentrx Therapeutics is on the frontline of cancer treatment, striving for breakthroughs in protein conjugate therapies. By utilizing novel ADC technologies, the company addresses persistent challenges in cancer care. Through their extensive pipeline of ADC candidates, Adcentrx aims to deliver first-in-class and best-in-class therapies that significantly enhance patient outcomes.\nFrequently Asked Questions\nWhat is ADRX-0706?\nADRX-0706 is an investigational Nectin-4 ADC designed to target solid tumors, using advanced i-Conjugation® technology to improve delivery and efficacy.\nWhat will be presented at the ASCO Annual Meeting?\nAdcentrx will showcase interim results from the Phase 1a trial of ADRX-0706, highlighting its safety, pharmacokinetics, and preliminary efficacy.\nHow does i-Conjugation® Technology work?\nThis proprietary technology enhances the stability and effectiveness of ADCs by utilizing high-performance linkers for optimized drug delivery to tumor cells.\nWhat types of cancers is ADRX-0706 targeting?\nADRX-0706 is currently being evaluated for its potential in treating urothelial, triple-negative breast, and cervical cancers.\nHow can I learn more about Adcentrx Therapeutics?\nFor further information about Adcentrx and its ADC technologies, you can visit their official website for updates on their innovative therapies.\nAbout The Author\nContact Evelyn Baker privately\nhere. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.\nAbout Investors Hangout\nInvestors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/\nThe content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please\ncontact us for corrections.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Health",
      "Science and Technology",
      "Human Interest"
    ],
    "topics": [
      "Health->cancer",
      "Health->health treatment and procedure",
      "Health->medical profession",
      "Science and Technology->medical research",
      "Science and Technology->scientific publication",
      "Science and Technology->biotechnology"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [],
      "locations": [],
      "organizations": [
        {
          "name": "American Society of Clinical Oncology",
          "sentiment": "none",
          "tickers": []
        },
        {
          "name": "ASCO",
          "sentiment": "none",
          "tickers": []
        }
      ]
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-04-24T02:31:46.954+03:00",
    "updated": "2025-04-24T02:31:46.954+03:00"
  }
]